Laserfiche WebLink
<br />HCA Contract No. K5885-04 Page 4 of 13 <br />SCHEDULE A-4 <br />Statement of Work <br />July 1, 2025 - June 30, 2026 <br />1. PURPOSE <br />Support a comprehensive treatment program for incarcerated individuals with Opioid Use Disorder <br />(OUD) and Alcohol Use Disorder (AUD), beginning with screening upon entry and ending with <br />seamless transition to the care in the community, with use of Medications for Opioid Use Disorder <br />(MOUD) and Medications for Alcohol Use Disorder (MAUD) at its core. <br />This Contract supports RCW 71.24.599: Opioid use disorder—City and county jails—Funding. <br />(wa.gov). <br />Health Equity - This program also intends to address inequities in treatment and recovery services <br />by providing medically necessary treatment to incarcerated individuals. Programs should <br />understand cultural barriers and provide culturally appropriate services. Additionally, this program <br />intends to identify stigma and educate to ensure ongoing collaboration and openness to change. <br />2. WORK EXPECTATIONS <br />Contractor shall ensure funds are responsibly used towards the Opioid Use Disorder (OUD) and <br />Alcohol Use Disorder (AUD) treatment programs in the jail and provide the community standard of <br />care, including, at a minimum, the following core components: <br />2.1. General Standard of Care <br />2.1.1. 2020 ASAM National Practice Guideline for the Treatment of Opioid Use Disorder ; <br />2.1.2. Guidelines for Managing Substance Withdrawal in Jails ; <br />2.1.3. For American Indian/Alaska Native (AI/AN) individuals receiving Medications for <br />Opioid Use Disorder (MOUD) and/or Medications for Alcohol Use Disorder (MAUD) <br />services, Contractor, shall coordinate with the individual’s Indian Health Care <br />Provider (IHCP) to ensure the IHCP can participate in treatment and discharge <br />planning, including continuity of care in the nearest IHCP clinically appropriate <br />setting for all AI/AN individuals participating in the program. <br />2.2. Intake <br />2.2.1. Screen all newly admitted individuals for risk of acute withdrawal from opioids and <br />alcohol upon intake. <br />2.2.2. MOUD, MAUD, and other medications which support the relief of withdrawal <br />symptoms, such as clonidine, anti-emetics, anti-diarrheals, and analgesics must be <br />offered to individuals at no charge to the individual. <br />2.2.3. Offer initiation of MOUD treatment to individuals who are physically dependent on <br />opioids, may have withdrawal symptoms or have disclosed recent use and <br />anticipate withdrawal. <br />2.2.4. Offer treatment for withdrawal with benzodiazepines to individuals entering the <br />facility who are physically dependent on alcohol, if clinically appropriate.